Search Results

You are looking at 101 - 110 of 197 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Karam Khaddour, Michael R. Chicoine, Jiayi Huang, Sonika Dahiya, and George Ansstas

reduction. The treatment course with trametinib and dabrafenib continued for a total of 9 months. The patient experienced mild pyrexia (grade I fever according to CTCAE version 5.0.), which required treatment interruption for 4 days before later resuming the

Full access

Michael Angarone and Michael G. Ison

transplantation: analysis of factors associated with infection . Oral Surg Oral Med Oral Pathol 1990 ; 70 : 286 – 293 . 60. Bergmann OJ Mogensen SC Ellermann-Eriksen S Ellegaard J . Acyclovir prophylaxis and fever during remission-induction therapy

Full access

who’ve been through the process already. The patient and family experience has been improved due to Moffitt’s nursing team’s efforts to provide dedicated education on the common side effects for CAR T-cell therapy, such as high fevers, neurotoxicity

Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma

65 years. Tumor flare reactions occurred in 71% of patients, but were grade 1 or 2 in nearly all cases. The most common grade 3 or 4 toxicity was neutropenia, which was reported in 49% of patients. Neutropenic fever occurred in 4 patients (6%). 24

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

severe chronic neutropenia) based on a randomized controlled trial involving 123 patients. 109 In this study, daily treatment with subcutaneously administered G-CSF normalized neutrophils in most patients and prevented fever, mouth ulcers, and infections

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

, although they were not severe and were reversible. These reactions included mild myalgias, facial flushing, low-grade fever, headache, bone discomfort, nausea, and dyspnea. 106 A side-effect profile of GM-CSF, completed several years later, reported a

Full access

Jennifer M. Hinkel, Edward C. Li, and Stephen L. Sherman

less than 20,000/μL for fever, sepsis, uncontrolled infections, a blood urea nitrogen of greater than 70, or veno-occlusive disease. One institution with a usual threshold of less than 10,000/μL increases this threshold to less than 20,000/μL for

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

in patients aged 70 years or older showed higher toxicity (neutropenic fever, hemorrhage, nausea, anorexia, and hypertension) in the elderly patients who received bevacizumab. 53 Moreover, the addition of bevacizumab did not confer a survival

Full access

Merav Bar and Jerald Radich

3.2 months, respectively. The most common side effects reported in the clinical trial include hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain, and nausea. Arterial thrombosis and liver toxicity were

Full access

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger, and Adam M. Petrich

: anaphylaxis 15 minutes into cycle 2, a delayed reaction 1 day after completing cycle 3, and an episode of rigors, fever, tachycardia, and hypotension at completion of cycle 3. 20 The patient in the present case report received her first cycle of brentuximab